At what gestational age is twin anemia polycythemia sequence (TAPS) typically diagnosed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of TAPS Diagnosis

Twin anemia polycythemia sequence (TAPS) is typically diagnosed in the late second or third trimester, with a median gestational age of approximately 23-24 weeks, though it can present at any time from 16 weeks through the end of the third trimester. 1, 2

Gestational Age at Diagnosis

  • TAPS can present at any time during the second or third trimesters, distinguishing it from twin-twin transfusion syndrome (TTTS), which typically presents earlier. 1

  • In a large international cohort of 249 cases, spontaneous TAPS was diagnosed antenatally at a median gestational age of 23.7 weeks (interquartile range 9.7-28.8 weeks; range 15.1-35.3 weeks). 2

  • TAPS occurs significantly later in pregnancy than TTTS, with median gestational age at diagnosis of 26.0 weeks for TAPS compared to 20.4 weeks for TTTS. 3

  • The condition most commonly manifests in the late second or third trimester, particularly after 20 weeks of gestation. 4

Surveillance Timing for Detection

  • Screening for TAPS should begin at 16 weeks of gestation using middle cerebral artery peak systolic velocity (MCA-PSV) Doppler measurements in all monochorionic twin pregnancies. 1

  • Surveillance should continue at least every 2 weeks throughout the second and third trimesters until delivery to detect TAPS at any stage. 1, 5

  • Once TAPS is diagnosed, monitoring should be scheduled weekly to assess disease progression and guide management decisions. 5

Clinical Context

  • Unlike TTTS, which has a more predictable gestational age window, TAPS has a broader and later presentation pattern, making consistent surveillance throughout pregnancy essential. 2, 3

  • Post-laser TTTS cases require particularly vigilant MCA-PSV surveillance as iatrogenic TAPS can develop after fetoscopic laser surgery, representing a substantial risk requiring another intervention. 1

  • The wide gestational age range at diagnosis (15-35 weeks) underscores the unpredictable nature of TAPS onset and the need for sustained monitoring protocols. 2

Important Caveats

  • TAPS is unlikely to be prenatally detected without systematic MCA-PSV evaluation, especially at earlier stages, making routine Doppler surveillance critical. 1

  • Approximately 12% of TAPS cases are diagnosed only postnatally, highlighting the challenge of antenatal detection even with surveillance protocols. 2

  • The later gestational age at diagnosis compared to TTTS does not indicate lower severity—overall mortality for TAPS is similar to TTTS despite its later onset. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Twin anemia-polycythemia sequence in a case of monoamniotic twins.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2013

Research

Consensus diagnostic criteria and monitoring of twin anemia-polycythemia sequence: Delphi procedure.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.